Amgen has acquired ChemoCentryx in a deal that includes lead molecule avacopan (Tavneos), a first-in-class orally bioavailable small molecule complement 5a receptor (C5aR) antagonist approved as an adjunctive treatment to standard of care therapy for adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In this article we review:
- the details of the deal
- the clinical context
- the discovery of the drug and target
this content is exclusive to
Premium members
Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.
